Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Chemotherapy-induced Nausea and Vomiting Drugs Market Financial Review: Fast Facts of You Should Know About Chemotherapy-induced Nausea and Vomiting Drugs Industry Analysis 2021

Monday, February 27, 2017 6:19
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Chemotherapy-induced Nausea and Vomiting Drugs Market Research Report covers the present scenario and the growth prospects of the Chemotherapy-induced Nausea and Vomiting Drugs Industry for 2017-2021. Chemotherapy-induced Nausea and Vomiting Drugs Market, has been prepared based on an in-depth market analysis with inputs from industry experts.

The report covers the market landscape and its growth prospects over the coming years and discussion of the key vendors effective in this market. To calculate the market size, the report considers the revenue generated from the sales of Chemotherapy-induced Nausea and Vomiting Drugs globally.

For further information on this report, please visit- http://www.marketreportsworld.com/10294043

The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.

 
Following Companies Are Key Players of the Chemotherapy-induced Nausea and Vomiting Drugs Market:

• GlaxoSmithKline

• Helsinn

• Heron Therapeutics

• Merck

• Tesaro

Other Prominent Vendors of Chemotherapy-induced Nausea and Vomiting Drugs Market Are:

• Acacia Pharma

• Aphios

• Baxter Healthcare

• Dr. Reddy’s Laboratories

• Eisai

• Especificos Stendhal

• F. Hoffmann-La Roche

• Kyowa Hakko Kirin

• Lee’s Pharmaceutical Holdings

“The high unmet medical need in the market has driven the R&D activities of existing as well as new vendors. Helsinn is one of the leading companies that has a strong pipeline of CINV drugs with two drug candidates in Phase III and Phase I stages. Helsinn has collaborated with Taiho Pharmaceutical for the development and commercialization of netupitant IV in Japan. Heron Therapeutics is developing HTX-019, currently in Phase I stage, for the prevention and treatment of CINV. In addition, new vendors such as Shin Nippon Biomedical Laboratories and Acacia Pharma are aggressively advancing their pipeline to launch new drugs during the forecast period. Shin Nippon Biomedical Laboratories and Acacia are developing granisetron intranasal and APD403, respectively. Both these drugs are in Phase II development stage. These pipeline drugs are expected to gain approval during the forecast period and will likely fuel the market growth.”

Ask Sample PDF of Chemotherapy-induced Nausea and Vomiting Drugs Market Report @http://www.marketreportsworld.com/enquiry/request-sample/10294043  

According to the report, the high unmet medical need in the market has driven the R&D activities of existing as well as new vendors. Helsinn is one of the leading companies that has a strong pipeline of CINV drugs with two drug candidates in Phase III and Phase I stages. Helsinn has collaborated with Taiho Pharmaceutical for the development and commercialization of netupitant IV in Japan. Heron Therapeutics is developing HTX-019, currently in Phase I stage, for the prevention and treatment of CINV. In addition, new vendors such as Shin Nippon Biomedical Laboratories and Acacia Pharma are aggressively advancing their pipeline to launch new drugs during the forecast period. Shin Nippon Biomedical Laboratories and Acacia are developing granisetron intranasal and APD403, respectively. Both these drugs are in Phase II development stage. These pipeline drugs are expected to gain approval during the forecast period and will likely fuel the market growth.
 

Report also presents Geographical Segmentation analysis of Chemotherapy-induced Nausea and Vomiting Drugs Market of Americas, APAC, EMEA region.

 

For Any Query, Contact Our Expert @ http://www.marketreportsworld.com/enquiry/pre-order-enquiry/10294043

Further, the report states that patent expiries result in the loss of market exclusivity of a drug, which will result in a rapid decline in its sales. This will further lead to the market entry of cost-effective generic versions that have a similar efficacy and safety profile as the branded therapy. The patents of majority of the CINV therapeutics have either expired or are set to expire at the end of the forecast period. For instance, Zofran by GlaxoSmithKline lost its patent exclusivity in 2005 and Kytril by F. Hoffmann-La Roche in 2007. This led to the market entry of their generics, reducing their sales. Similarly, EMEND by Merck and Aloxi by Helsinn lost their patent exclusivities in April 2015, leading to the availability of their generics in the market. EMEND reported a YoY decline of 3.3% owing to patent expiry covering product’s oral dosage form in 2015. Therefore, loss of patent expiries will substantially impact the market growth.

Key questions answered in Chemotherapy-induced Nausea and Vomiting Drugs market report:

  • What will the Chemotherapy-induced Nausea and Vomiting Drugs market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving Chemotherapy-induced Nausea and Vomiting Drugs market?
  • What are the challenges to Chemotherapy-induced Nausea and Vomiting Drugs market growth?
  • Who are the key vendors in Chemotherapy-induced Nausea and Vomiting Drugs market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

 

No of Pages: 77

Price of Report: $ 3500 (Single User License)

Purchase Report @ http://www.marketreportsworld.com/purchase/10294043

About Market Reports World:

Market Reports World is the credible source for gaining the market research reports that will exponentially accelerate your business. We are among the leading report resellers in the business world committed towards optimizing your business. The reports we provide are based on a research that covers a magnitude of factors such as technological evolution, economic shifts and a detailed study of market segments.

Contact–

Mr. Ameya Pingaley

Market Reports World

+1 408 520 9750

Email – [email protected]

http://www.marketreportsworld.com

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories
 

Featured

 

Top Global

 

Top Alternative

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.